Investment case
Pacific Biosciences of California, Inc.
PACB · 3 developments mapped · last assessed 2026-09-25
Market Ontology has mapped 3 macro, policy, and market developments to Pacific Biosciences of California, Inc. since 2026-09-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for PACB yet, so no modelled value is shown. The PACB valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run PACB on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
Increased demand for genomic sequencing and synthetic biology tools and consumables as the sector grows and secures more funding.
· Moves market size growth, equipment utilization
- Open question
Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal
Increased investor interest in genomics/synthetic biology tools, potential for similar partnerships.
· Moves market growth for genomics tools, investor sentiment towards biotech innovation
What changed, by assumption
- 2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal
- 2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform
- 2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Bullish | 3-12m | 0.20 |
| 2026-09-20 | Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal | watch | 3-12m | 0.30 |
| 2026-09-19 | Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab Platform | watch | 3-12m | 0.30 |